Trahearn N, Sakr C, Banerjee A, Lee S, Baker A, Kocher H
J Pathol. 2025; 265(2):198-210.
PMID: 39788558
PMC: 11717494.
DOI: 10.1002/path.6378.
Bai Y, Li T, Wang Q, You W, Yang H, Xu X
EMBO Mol Med. 2024; 16(2):334-360.
PMID: 38177537
PMC: 10897227.
DOI: 10.1038/s44321-023-00015-9.
Abedizadeh R, Majidi F, Khorasani H, Abedi H, Sabour D
Cancer Metastasis Rev. 2023; 43(2):729-753.
PMID: 38112903
DOI: 10.1007/s10555-023-10158-3.
Veen T, Kanani A, Lea D, Soreide K
Cancer Immunol Immunother. 2023; 72(10):3135-3147.
PMID: 37528319
PMC: 10491705.
DOI: 10.1007/s00262-023-03480-w.
Kumar R, Kim J, Deek M, Eskander M, Gulhati P, In H
Curr Oncol. 2023; 30(7):6432-6446.
PMID: 37504333
PMC: 10378032.
DOI: 10.3390/curroncol30070473.
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art.
Provinciali N, Greppi M, Pesce S, Rutigliani M, Briata I, Buttiron Webber T
Front Immunol. 2023; 13:1094017.
PMID: 36601114
PMC: 9806340.
DOI: 10.3389/fimmu.2022.1094017.
T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Campana L, Mansoor W, Hill J, Macutkiewicz C, Curran F, Donnelly D
Cancers (Basel). 2022; 14(23).
PMID: 36497365
PMC: 9740634.
DOI: 10.3390/cancers14235883.
Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.
Ding Y, Wang Z, Zhou F, Chen C, Qin Y
Front Oncol. 2022; 12:987302.
PMID: 36248998
PMC: 9561929.
DOI: 10.3389/fonc.2022.987302.
Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.
Santiago-Sanchez G, Hodge J, Fabian K
Front Immunol. 2022; 13:993624.
PMID: 36159809
PMC: 9492957.
DOI: 10.3389/fimmu.2022.993624.
Augmented Antitumor Effect of Unripe Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model.
Lee E, Yang J, Choi J, Chung H
Cells. 2022; 11(18).
PMID: 36139451
PMC: 9496898.
DOI: 10.3390/cells11182876.
A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient/microsatellite instability-high metastatic colon cancer: A case report.
Igaue S, Okuno T, Ishibashi H, Nemoto M, Hiyoshi M, Kawasaki H
Oncol Lett. 2022; 24(1):211.
PMID: 35720492
PMC: 9178690.
DOI: 10.3892/ol.2022.13332.
Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
Xin B, Yang M, Wu P, Du L, Deng X, Hui E
Hepatology. 2021; 76(3):630-645.
PMID: 34860431
PMC: 9163212.
DOI: 10.1002/hep.32266.
Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee E, Kim J, Kim T, Kim Y, Pak M, Jeon C
Front Immunol. 2021; 12:737076.
PMID: 34659228
PMC: 8511399.
DOI: 10.3389/fimmu.2021.737076.
ACKR4 in Tumor Cells Regulates Dendritic Cell Migration to Tumor-Draining Lymph Nodes and T-Cell Priming.
Wangmo D, Premsrirut P, Yuan C, Morris W, Zhao X, Subramanian S
Cancers (Basel). 2021; 13(19).
PMID: 34638505
PMC: 8507805.
DOI: 10.3390/cancers13195021.
Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer.
Dagenborg V, Marshall S, Grzyb K, Fretland A, Lund-Iversen M, Maelandsmo G
Front Oncol. 2021; 11:671629.
PMID: 34178659
PMC: 8220067.
DOI: 10.3389/fonc.2021.671629.
